Breaking News Instant updates and real-time market news.

ABMD

Abiomed

$387.40

0.42 (0.11%)

, WYN

Wyndham

$110.89

2.4 (2.21%)

04:55
05/31/18
05/31
04:55
05/31/18
04:55

Abiomed to enter S&P 500 index on May 31

S&P MidCap 400 constituent ABIOMED (ABMD) will replace Wyndham Worldwide (WYN) in the S&P 500, Wyndham Worldwide will replace Microsemi Corp. (MSCC) in the S&P MidCap 400, and PRA Health Sciences Inc. (PRAH) will replace ABIOMED in the S&P MidCap 400 effective prior to the open of trading on Thursday, May 31. Wyndham Hotels & Resorts (WH) will be added to the S&P MidCap 400 effective prior to the open of trading on Friday, June 1, replacing GameStop Inc. (GME), which will be removed from the S&P MidCap 400 effective prior to the open of trading on Monday, June 4, and GameStop will replace Fred's Inc. (FRED) in the S&P SmallCap 600 also effective prior to the open of trading on June 4. New S&P MidCap 400 constituent Wyndham Worldwide, which is changing its name to Wyndham estinations Inc. and its ticker symbol to WYND, is spinning off Wyndham Hotels & Resorts in a transaction expected to be effective on June 1. Post spin-off, Wyndham Destinations will remain in the S&P MidCap 400. GameStop has a market capitalization more representative of the small-cap market space. Fred's is ranked near the bottom of the S&P SmallCap 600. Perspecta Inc. (PRSP) will replace Office Depot Inc. (ODP) in the S&P MidCap 400, and Office Depot will replace Roadrunner Transportation Systems Inc. (RRTS) in the S&P SmallCap 600 effective prior to the open of trading on Monday, June 4. S&P 500 constituent DXC Technology Co. (DXC) is spinning off Perspecta in a transaction expected to be effective on June 1. Post spin-off, DXC Technology will remain in the S&P 500. Office Depot has a market capitalization more representative of the small-cap market space. Roadrunner Transportation Systems is ranked near the bottom of the S&P SmallCap 600.

ABMD

Abiomed

$387.40

0.42 (0.11%)

WYN

Wyndham

$110.89

2.4 (2.21%)

MSCC

Microsemi

$68.74

(0.00%)

PRAH

PRA Health

$88.72

3.52 (4.13%)

GME

GameStop

$13.44

0.38 (2.91%)

FRED

Fred's

$1.55

-0.005 (-0.32%)

PRSP

Perspecta

$0.00

(0.00%)

RRTS

Roadrunner

$1.81

-0.015 (-0.82%)

DXC

DXC Technology

$92.68

2.825 (3.14%)

  • 31

    May

  • 31

    May

  • 05

    Jun

  • 12

    Jun

ABMD Abiomed
$387.40

0.42 (0.11%)

05/29/18
JEFF
05/29/18
NO CHANGE
Target $460
JEFF
Buy
Abiomed price target raised to $460 from $400 at Jefferies
Jefferies analyst Raj Denhoy raised his price target for Abiomed to $460 after after attending EuroPCR this year in Paris. Interest in mechanical support with Impella is global, with clinicians in every country doing percutaneous coronary intervention or treating cardiogenic shock increasingly recognizing the value of the technology, Denhoy tells investors in a research note. He believes reimbursement remains the only hurdle, but feels denying access is becoming harder to justify. The analyst keeps a Buy rating on shares of Abiomed.
04/04/18
GSCO
04/04/18
INITIATION
Target $332
GSCO
Buy
Abiomed initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Issac Ro started Abiomed with a Buy rating and $332 price target.
04/25/18
PIPR
04/25/18
NO CHANGE
PIPR
Overweight
Piper says IPPS rates appear negative, but are really neutral for Abiomed
After Abiomed issued an 8k discussing the Centers for Medicare and Medicaid Services' proposed Inpatient Prospective Payment System, or IPPS, rates for Impella, Piper Jaffray analyst Matt O'Brien said the rates look negative "at first blush." However, when considering that very few Impella cases are billed to the DRG code for which the CMS proposed a cut of 24%, he said he views the proposed IPPS as "fairly neutral" for Abiomed. Adding that the code where most Impella cases are performed is proposed to be up about 3% in the current rule, O'Brien said he would take advantage of any weakness to start or build Abiomed positions. He keeps an Overweight rating on the shares.
05/03/18
PIPR
05/03/18
NO CHANGE
Target $360
PIPR
Overweight
Abiomed price target raised to $360 from $300 at Piper Jaffray
Piper Jaffray analyst Matt O'Brien raised his price target for Abiomed to $360 saying this morning's Q4 results easily beat his estimates. The momentum in using Impella to treat patients "remains strong" and there are new products and geographies that should continue to drive sales, O'Brien tells investors in a post-earnings research note. The analyst, while admitting the valuation is "hefty," reiterates an Overweight rating on Abiomed. He continues to encourage investors to own the name.
WYN Wyndham
$110.89

2.4 (2.21%)

05/07/18
STFL
05/07/18
NO CHANGE
Target $131
STFL
Buy
Wyndham selloff after earnings overdone, says Stifel
Stifel analyst Simon Yarmak said Wyndham's (WYN) Q1 earnings release was a headline beat and he viewed the incremental information as largely positive, stating that he sees the selloff since as being overdone and recommends buying the shares ahead of the spinoff. While the Marriott Vacations (VAC) and ILG (ILG) deal may have disappointed some investors with respect to synergies, the acquisition price should have a positive read-through to Wyndham, added Yarmak. He lowered his price target on Wyndham to $131 from $135 and keeps a Buy rating on the shares.
05/18/18
FBCO
05/18/18
INITIATION
Target $116
FBCO
Neutral
Wyndham initiated with a Neutral at Credit Suisse
Credit Suisse analyst Cameron McKnight started Wyndham with a Neutral rating and $116 price target, stating in a note to investors sent earlier this morning that while he is positive on the timeshare space, he sees a mix of fundamental positives and challenges for Wyndham, the largest timeshare company which will shortly spin off its hotel business.
04/02/18
OPCO
04/02/18
INITIATION
Target $135
OPCO
Outperform
Wyndham initiated with an Outperform at Oppenheimer
Oppenheimer analyst Ian Zaffino started Wyndham Worldwide (WYN) with an Outperform rating and $135 price target, calling the company the leader in the economy/upper-economy hotel space and saying he believes the planned acquisition of La Quinta (LQ) will also make it the leader in the premier midscale segment.
03/23/18
STFL
03/23/18
NO CHANGE
Target $135
STFL
Buy
Wyndham shares have more room to run, says Stifel at Stifel
Stifel analyst Simon Yarmak took a deep dive into Wyndham Worldwide's Form 10 for the previously announced spin-off of Wyndham Hotels & Resorts, which is expected in Q2. In a research note to investors, Yarmak, who has a Buy rating and $135 price target on shares, said shares have had a "good" run, with shares up 21.3% vs. the S&P since the spin was announced in August, and sees more room for shares to run. He sees upside heading into the spinoff.
MSCC Microsemi
$68.74

(0.00%)

03/06/18
PIPR
03/06/18
DOWNGRADE
Target $68.78
PIPR
Neutral
Microsemi downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Harsh Kumar downgraded Microsemi (MSCC) to Neutral citing the pending takeover by Microchip (MCHP). The analyst does not believe another company will try to outbid Microchip's current agreement with Microsemi. He lowered his price target for Microsemi shares to $68.78 from $70 and expects the deal will close in Q2.
03/05/18
03/05/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Amag Pharmaceuticals (AMAG) downgraded to Hold from Buy at Jefferies with analyst Eun Yang citing valuation. 2. Finisar (FNSR) downgraded to Outperform from Strong Buy at Raymond James. 3. LifePoint (LPNT) downgraded to Market Perform from Outperform at Leerink with analyst Ana Gupte saying increased investments over the next 12 months to capture additional volume growth will challenge free cash flow and share price appreciation. 4. Microsemi (MSCC) downgraded to Sector Weight from Overweight at KeyBanc, to Neutral from Buy at Mizuho and to Market Perform from Outperform at BMO Capital. 5. Vectrus (VEC) downgraded to Hold from Buy at Drexel Hamilton with the firm citing valuation. click here.
03/05/18
BMOC
03/05/18
DOWNGRADE
Target $68.78
BMOC
Market Perform
Microsemi downgraded to Market Perform from Outperform at BMO Capital
BMO Capital analyst Ambrish Srivastava downgraded Microsemi (MSCC) to Market Perform from Outperform following the bid by Microchip (MCHP) at $68.78 per share. Srivastava adds that he does anticipate a potential competitive bid for the company.
04/25/18
NEED
04/25/18
NO CHANGE
NEED
Full ban of sales to Huawei 'highly improbable,' says Needham
Needham analysts Alex Henderson and N. Quinn Bolton said they sees the chances of an outright ban of sales to Huawei as "extremely low," adding that it is their understanding the probe into Huawei has been ongoing for the last two years while noting that the ZTE probe took over five years to complete. The ironic impact of any escalation in trade tension could be an increase in demand from Huawei to build an inventory buffer should there be a supply disruption, added the analysts, who also say they would not be surprised to see a trade agreement with China include a resolution of the ZTE (ZTCOY) ban and possibly an agreement on the scope of action against Huawei.
PRAH PRA Health
$88.72

3.52 (4.13%)

10/30/17
KEYB
10/30/17
NO CHANGE
Target $93
KEYB
Overweight
PRA Health price target raised to $93 from $86 at KeyBanc
KeyBanc analyst Donald Hooker raised his price target for PRA Health to $93 from $86 to reflect the stronger than expected trends at Symphony Health and over 15% EBITDA growth in 2018 and 2019. The analyst reiterates an Overweight rating on the shares.
12/11/17
LEHM
12/11/17
INITIATION
Target $94
LEHM
Overweight
PRA Health initiated with an Overweight at Barclays
Barclays analyst Jack Meehan started PRA Health Sciences with an Overweight rating and $94 price target. The analyst views the stock's valuation as attractive in the context of the company's "market-leading growth rates." He believes the integration of data into clinical trials is going to become a "need to have."
12/14/17
MUFG
12/14/17
INITIATION
Target $102
MUFG
Overweight
PRA Health initiated with an Overweight at MUFG
MUFG analyst Jason Twizell started PRA Health with an Overweight rating and $102 price target. The analyst finds the company's premium valuation justified given its high-teens percentage revenue growth outlook and "consistent" execution.
01/24/18
MZHO
01/24/18
DOWNGRADE
Target $86
MZHO
Neutral
PRA Health downgraded to Neutral from Buy at Mizuho
Mizuho analyst Ann Hynes downgraded PRA Health to Neutral citing valuation and trimmed its price target to $86 from $87.
GME GameStop
$13.44

0.38 (2.91%)

05/22/18
LOOP
05/22/18
NO CHANGE
Target $14
LOOP
Hold
GameStop LBO at 'sizable premium' would see attractive return, says Loop Capital
Loop Capital analyst Anthony Chukumba says that after years of underperformance, Gamestop now trades at "by far the lowest valuation multiple" in his entire coverage universe. Given that shareholders have become "more vocal", the analyst notes that a potential leveraged buyout at $19 per share could be a "feasible alternative" that could generate attractive returns, though he also adds that the absence of a "clearly defined exit strategy" make the prospects of such deal questionable. Chukumba keeps his Hold rating and $14 price target on Gamestop.
05/22/18
FBCO
05/22/18
NO CHANGE
Target $15
FBCO
Neutral
GameStop price target lowered to $15 from $20 at Credit Suisse
Credit Suisse analyst Seth Sigman lowered his price target for GameStop to $15 from $20 as it faces some difficult comparisons in the core business this year, continued uncertainty on the software side, and challenges in mobile. Further, the analyst notes he has yet to see clear signs that earnings can stabilize. Sigman reiterates a Neutral rating on the shares.
05/16/18
LOOP
05/16/18
NO CHANGE
Target $14
LOOP
Hold
'Nice' to see GameStop shareholder more vocal, but unclear of result, says Loop Capital
Loop Capital analyst Anthony Chukumba notes that according to CNBC, hedge fund Tiger Global Management sent a letter to GameStop's board of directors urging the company to launch a strategic review in the wake of recent senior management departures. The analyst is "not terribly surprised" to see one of GameStop's shareholders become more vocal given the recent underperformance and senior management turnover. While he is unclear whether there would be any takers for the struggling Technology Brands and views Gamestop's International operations as a core business, Chukumba believes many of Tiger Global's demands make sense. Nonetheless, the analyst is not confident Tiger Global's letter will result in significant shareholder value creation given the fact the fund has a relatively small position in GameStop. He reiterates a Hold rating and $14 price target on the shares.
05/11/18
BARD
05/11/18
NO CHANGE
Target $18
BARD
Outperform
GameStop CEO change could push board to consider alternatives, says Baird
After GameStop announced the resignation of CEO Mike Mauler and appointment of long-time executive and executive chairman Dan DeMatteo as interim CEO, Baird analyst Colin Sebastian said he does not believe the change will impact the company's strategic direction. He also thinks that another CEO transition could push the board to consider strategic alternatives, especially given that the share price is not reflecting much confidence in the current operations. Sebastian maintains an Outperform rating and $18 price target on GameStop.
FRED Fred's
$1.55

-0.005 (-0.32%)

08/25/17
08/25/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Walgreens Boots Alliance (WBA) initiated with a Buy and CVS Health (CVS) and Fred's (FRED) initiated with a Hold at Loop Capital. 2. Adobe (ADBE), Intuit (INTU), GoDaddy (GDDY) initiated with a Buy at Jefferies, while Mindbody (MB) was initiated with a Hold. 3. New Oriental Education (EDU), Bright Scholar (BEDU) and TAL Education (TAL) initiated with Overweight ratings at Morgan Stanley. 4. WellCare (WCG) coverage assumed with an Overweight at Cantor. 5. Dollar Tree (DLTR) and Dollar General (DG) reinstated with Buy ratings at BofA/Merrill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/30/18
LOOP
04/30/18
NO CHANGE
Target $4
LOOP
Hold
Fred's CEO resignation 'fire but no sale,' says Loop Capital
In a research note titled "CEO resigns - Fire but no sale," Loop Capital analyst Andrew Wolf notes that Fred's (FRED) has announced the resignation of Chief Executive Officer Michael Bloom, effective as of April 24, 2018. Joseph Anto, Fred's Executive Vice President and Chief Financial Officer, will serve as Interim Chief Executive Officer. Additionally, the analyst points out that Alden Capital owns 24% of Fred's shares and its President, Heath Freeman, is now Chairman of the Board of Fred's. According to Freeman in a press release, "After the Company was not able to purchase certain assets from the Rite Aid Corporation (RAD)...the timing was right, both for Mike [Bloom] and the Company, for him to step down." Wolf reiterates a Hold rating and $4 price target on Fred's shares.
08/24/17
LOOP
08/24/17
INITIATION
Target $6
LOOP
Hold
Fred's initiated with a Hold at Loop Capital
Loop Capital analyst Andrew Wolf started Fred's with a Hold rating and $6 price target, as he believes the company lacks earnings visibility and sees the stock staying "about flat" over the next 6-12 months.
12/07/17
LOOP
12/07/17
NO CHANGE
Target $4
LOOP
Hold
Fred's price target lowered to $4 from $6 at Loop Capital
Loop Capital analyst Andrew Wolf lowered his price target on Fred's to $4 after a Q3 earnings miss, lower than expected sales, disappointing comps, and a 141bps gross margin contraction. Wolf cites inventory adjustments and competitive price pressures behind the disappointing results but adds that customer traffic has recently turned around. The analyst keeps his Hold rating on Fred's, saying his new price target already discounts the early stage turnaround that he anticipates for 2018.
PRSP Perspecta
$0.00

(0.00%)

RRTS Roadrunner
$1.81

-0.015 (-0.82%)

DXC DXC Technology
$92.68

2.825 (3.14%)

05/30/18
MSCO
05/30/18
NO CHANGE
Target $114
MSCO
Overweight
DXC Technology selloff appears overdone, says Morgan Stanley
Morgan Stanley analyst Brian Essex attributes the weakness yesterday and prior to the holiday weekend in shares of DXC Technology to investor confusion around the mechanics of the USPS spin and guidance offered on the call. However, he noted that the company's FY19 guidance was for the stand alone DXC business and that the two months of USPS operations ending in May will be accounted for in discontinued operations for Q1. The company's guidance implies flat revenue with margin expansion for FY19, added Essex, who would be a buyer of DXC shares and keeps an Overweight rating and $114 price target on the stock.
05/30/18
KEYB
05/30/18
NO CHANGE
KEYB
Overweight
KeyBanc remains bullish on DXC Technology amid recent selloff
KeyBanc analyst Arvind Ramnani notes that DXC Technology shares have been pressured over the past week, which he sees as an attractive entry point. The analyst believes the stock has pulled back due to non-fundamental factors, including investors incorrectly assuming FY19 guidance includes two months of United States public sector financials and misunderstanding that regular-way "DXC" includes Prespecta rights while when-issued "DXC WI" excludes Prespecta rights. Ramnani reiterates an Overweight rating on the shares.
05/30/18
SBSH
05/30/18
NO CHANGE
SBSH
Buy
DXC Technology fundamentals unchanged despite recent selloff, says Citi
Citi analyst Ashwin Shirvaikar recommends buying shares of DXC Technology following the recent weakness. He notes the stock is down 10% since earnings and 14% since Perspecta's investor day. Perspecta's investor day and DXC's fiscal 2019 outlook yielded outlooks largely in-line with expectations, meaning the company's fundamentals are unchanged, Shirvaikar tells investors in a research note. DXC's ongoing spin-merge was generally considered a positive catalyst but this has not materialized, which has led to investor frustration, the analyst adds. He sees "considerable confusion" but "no good reasons" for the stock weakness. As such, Shirvaikar recommends buying DXC Technology.
05/30/18
RHCO
05/30/18
NO CHANGE
Target $105
RHCO
Buy
DXC Technology price target lowered to $105 from $115 at SunTrust
SunTrust analyst Frank Atkins lowered his price target on DXC Technology to $105 after its in-line Q4 results and reflecting the reduced consensus for revenues and guidance. The analyst keeps his Buy rating however, saying he was "encouraged" by the margin guidance. Longer term, Atkins sees DXC Technology's potential driving "substantial" earnings growth of about 18% while the company continues "optimizing in-house support, reducing real estate footprint, and enhancing operational efficiencies."

TODAY'S FREE FLY STORIES

AERI

Aerie Pharmaceuticals

$58.50

0.1 (0.17%)

, AGN

Allergan

$191.34

-1.11 (-0.58%)

04:55
09/22/18
09/22
04:55
09/22/18
04:55
Conference/Events
European Society of Retina Specialists to hold a conference »

18th Congress of EURETINA…

AERI

Aerie Pharmaceuticals

$58.50

0.1 (0.17%)

AGN

Allergan

$191.34

-1.11 (-0.58%)

ALIM

Alimera Sciences

$1.07

(0.00%)

BABY

Natus Medical

$34.45

-0.2 (-0.58%)

BHC

Bausch Health

$24.92

-0.07 (-0.28%)

BAYRY

Bayer

$0.00

(0.00%)

ELXMF

Ellex Medical Lasers

$0.00

(0.00%)

GKOS

Glaukos

$58.78

-1.69 (-2.79%)

IRIX

IRIDEX

$6.52

0.08 (1.24%)

JNJ

Johnson & Johnson

$142.85

0.85 (0.60%)

NITE

Nightstar Therapeutics

$25.64

-1.71 (-6.25%)

NVS

Novartis

$85.46

-0.505 (-0.59%)

OCUL

Ocular Therapeutix

$6.45

0.03 (0.47%)

RHHBY

Roche

$0.00

(0.00%)

SHPG

Shire

$178.32

-1.68 (-0.93%)

STAA

STAAR Surgical

$47.00

-0.9 (-1.88%)

TMDI

Titan Medical

$2.24

0.02 (0.90%)

TTNP

Titan Pharmaceuticals

$0.22

-0.2833 (-56.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

  • 25

    Sep

  • 27

    Sep

  • 01

    Oct

  • 03

    Oct

  • 09

    Oct

  • 16

    Oct

  • 22

    Oct

  • 28

    Oct

  • 29

    Oct

  • 15

    Nov

  • 27

    Nov

  • 21

    Dec

  • 28

    Dec

  • 15

    Feb

  • 25

    Feb

CDTI

CDTi

$0.34

0.01 (3.08%)

18:15
09/21/18
09/21
18:15
09/21/18
18:15
Hot Stocks
CDTi sees September 21 as effective date of reverse stock split »

CDTi Advanced Materials…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DUK

Duke Energy

$79.82

-0.81 (-1.00%)

18:08
09/21/18
09/21
18:08
09/21/18
18:08
Hot Stocks
Duke Energy restored nearly 1.8M outages in NC, SC during past week »

Duke Energy crews today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 02

    Oct

  • 03

    Oct

  • 04

    Oct

  • 11

    Nov

JNJ

Johnson & Johnson

$142.85

0.85 (0.60%)

18:01
09/21/18
09/21
18:01
09/21/18
18:01
Hot Stocks
Johnson & Johnson's Janssen discloses phase 3 study results of Esketamine »

The Janssen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 28

    Oct

UAL

United Continental

$89.94

0.8 (0.90%)

17:39
09/21/18
09/21
17:39
09/21/18
17:39
Periodicals
United pilots refuse contract changes on regional routes, Reuters says »

United Airlines pilots…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

XLE

Energy Select Sector SPDR

$75.11

0.5132 (0.69%)

, XLU

Utilities SPDR

$53.04

0.2049 (0.39%)

17:36
09/21/18
09/21
17:36
09/21/18
17:36
General news
Week ending ETF Scorecard: Materials outperform, Utlilites slump »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$75.11

0.5132 (0.69%)

XLU

Utilities SPDR

$53.04

0.2049 (0.39%)

IYR

DJ US Real Estate Index Fund

$81.88

-0.06 (-0.07%)

XLP

Consumer Staples Sector SPDR

$55.02

0.1285 (0.23%)

XLY

Consumer Discretionary Sector SPDR

$116.98

-0.4288 (-0.37%)

XLB

S&P Select Materials SPDR

$60.54

-0.1312 (-0.22%)

XLF

Financial Select Sector

$28.73

-0.1175 (-0.41%)

XLV

Health Care Select Sector SPDR

$94.26

0.1571 (0.17%)

XLK

Technology Select Sector SPDR

$74.68

-0.2056 (-0.27%)

XLI

Industrial Select Sector SPDR

$79.71

0.2338 (0.29%)

GLD

SPDR Gold Trust

$113.48

-0.77 (-0.67%)

SLV

iShares Silver Trust

$13.44

-0.01 (-0.07%)

USO

United States Oil Fund

$14.95

0.145 (0.98%)

UNG

United States Natural Gas Fund

$24.60

0.235 (0.96%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$86.24

0.05 (0.06%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$114.72

0.04 (0.03%)

TLT

iShares 20+ Year Treasury Bond Fund

$117.12

-0.02 (-0.02%)

IEF

iShares 7-10 Year Treasury Bond ETF

$101.00

0.03 (0.03%)

SHY

iShares 1-3 Year Treasury Bond

$83.05

0.02 (0.02%)

IWD

iShares Russell 1000 Value

$129.51

0.13 (0.10%)

IWF

iShares Russell 1000 Growth

$155.30

-0.55 (-0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OHGI

One Horizon Group

$0.18

-0.0088 (-4.63%)

17:34
09/21/18
09/21
17:34
09/21/18
17:34
Syndicate
Breaking Syndicate news story on One Horizon Group »

One Horizon Group files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYTX

Cytori Therapeutics

$0.41

-0.033 (-7.38%)

17:31
09/21/18
09/21
17:31
09/21/18
17:31
Syndicate
Breaking Syndicate news story on Cytori Therapeutics »

Cytori Therapeutics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEM

Newmont Mining

$31.56

0.05 (0.16%)

17:22
09/21/18
09/21
17:22
09/21/18
17:22
Syndicate
Breaking Syndicate news story on Newmont Mining »

Newmont Mining files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 25

    Oct

CB

Chubb

$139.87

-0.05 (-0.04%)

17:22
09/21/18
09/21
17:22
09/21/18
17:22
Hot Stocks
Chubb CEO Greenberg sells $8.6M in common stock »

Chubb CEO Evan Greenberg…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VTVT

vTv Therapeutics

$0.80

0.0096 (1.21%)

17:21
09/21/18
09/21
17:21
09/21/18
17:21
Hot Stocks
vTv says FDA advised that azeliragon efficacy be shown in at least 2 trials »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VYGR

Voyager Therapeutics

$18.21

-0.27 (-1.46%)

17:17
09/21/18
09/21
17:17
09/21/18
17:17
Hot Stocks
Breaking Hot Stocks news story on Voyager Therapeutics »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNRC

Generac

$57.99

-0.02 (-0.03%)

17:16
09/21/18
09/21
17:16
09/21/18
17:16
Hot Stocks
Generac announces new $250M share repurchase program »

The company announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GBNK

Guaranty Bancorp

$30.20

-0.5 (-1.63%)

, IBTX

Independent Bank

$67.60

-1.15 (-1.67%)

17:13
09/21/18
09/21
17:13
09/21/18
17:13
Conference/Events
Independent Bank to host special shareholder meeting »

Special Shareholder…

GBNK

Guaranty Bancorp

$30.20

-0.5 (-1.63%)

IBTX

Independent Bank

$67.60

-1.15 (-1.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

HRS

Harris

$164.33

1.685 (1.04%)

17:13
09/21/18
09/21
17:13
09/21/18
17:13
Hot Stocks
Harris awarded $255.4M Department of Defense contract »

Harris Corp has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PMBC

Pacific Mercantile Bancorp

$9.25

-0.5 (-5.13%)

17:10
09/21/18
09/21
17:10
09/21/18
17:10
Hot Stocks
Breaking Hot Stocks news story on Pacific Mercantile Bancorp »

FJ Capital Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

WSC

WillScot

$17.10

-0.05 (-0.29%)

17:10
09/21/18
09/21
17:10
09/21/18
17:10
Syndicate
Breaking Syndicate news story on WillScot »

WillScot files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DTEA

DAVIDsTEA

$2.50

-0.9 (-26.47%)

17:09
09/21/18
09/21
17:09
09/21/18
17:09
Hot Stocks
Breaking Hot Stocks news story on DAVIDsTEA »

TDM Asset Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NYT

New York Times

$23.45

0.3 (1.30%)

, EXPE

Expedia

$133.73

-0.77 (-0.57%)

17:08
09/21/18
09/21
17:08
09/21/18
17:08
Hot Stocks
Expedia president Bhutani joins New York Times board »

The New York Times…

NYT

New York Times

$23.45

0.3 (1.30%)

EXPE

Expedia

$133.73

-0.77 (-0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBTX

Independent Bank

$67.60

-1.15 (-1.67%)

, GBNK

Guaranty Bancorp

$30.20

-0.5 (-1.63%)

17:08
09/21/18
09/21
17:08
09/21/18
17:08
Conference/Events
Guaranty Bancorp to host special shareholder meeting »

Special Shareholder…

IBTX

Independent Bank

$67.60

-1.15 (-1.67%)

GBNK

Guaranty Bancorp

$30.20

-0.5 (-1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

MPC

Marathon Petroleum

$83.37

1.44 (1.76%)

, ANDV

Andeavor

$154.80

2.19 (1.44%)

17:01
09/21/18
09/21
17:01
09/21/18
17:01
Conference/Events
Andeavor to host special shareholder meeting »

Special Shareholder…

MPC

Marathon Petroleum

$83.37

1.44 (1.76%)

ANDV

Andeavor

$154.80

2.19 (1.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 24

    Sep

ANDV

Andeavor

$154.80

2.19 (1.44%)

, MPC

Marathon Petroleum

$83.37

1.44 (1.76%)

16:59
09/21/18
09/21
16:59
09/21/18
16:59
Conference/Events
Marathon Petroleum to host special shareholder meeting »

Special Shareholder…

ANDV

Andeavor

$154.80

2.19 (1.44%)

MPC

Marathon Petroleum

$83.37

1.44 (1.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

EPRT

Essential Properties Realty Trust

$14.49

-0.015 (-0.10%)

16:45
09/21/18
09/21
16:45
09/21/18
16:45
Hot Stocks
Breaking Hot Stocks news story on Essential Properties Realty Trust »

Integrated Core…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBSI

Barrett Business

$63.67

0.04 (0.06%)

16:43
09/21/18
09/21
16:43
09/21/18
16:43
Hot Stocks
SEC says Barrett Business to pay $1.5M penalty over improper accounting »

The Securities and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIGA

Siga Technologies

$7.25

0.5 (7.41%)

16:42
09/21/18
09/21
16:42
09/21/18
16:42
Conference/Events
Siga Technologies to host business news update conference call »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.